Poisonous Plant Research Laboratory REGISTRATION NUMBER: 87-G-0001 EXPLANATION FOR THE USE OF ANIMALS LISTED IN COLUMN E

The 2016 Annual Report of Research Facility for the Poisonous Plant Research Laboratory indicates laboratory mice have been used in studies involving pain and distress for which the use of appropriate anesthetic, analgesic or tranquilizing drugs would have adversely affected the procedures, results or interpretation of the research. Research conducted at this institution involves experiments to determination the toxicity of plant compounds using a median lethal dose (LD₅₀) protocol in a laboratory mouse model. In the case of all LD₅₀ experiments, animals are intensively monitored during the experiment. Previous experience with LD₅₀ experiments in laboratory mice at this laboratory have provided specific criteria for each plant compound indicating likely death. Laboratory mice meeting these criteria are euthanized to minimize pain and distress. All compounds used with the animals in this report are extremely acute toxins, with death occurring within minutes after IV injection. All animals that survive are quickly euthanized after it is apparent they survived the treatment. Therefore, any pain and distress experienced by the animals is minimized by euthanizing the animals.

Some of the LD₅₀ experiments performed at the Poisonous Plant Research Laboratory involve the investigation of plant compounds for which the toxicity and mechanism of action is not known. The experimental status of the plant compounds being tested means that little or no information is available regarding possible drug-drug interactions. Co-administration of pain relieving compounds alters their toxicity, and therefore would skew the true toxicity values of the compounds. Therefore, the use of pain relieving substances is avoided in these experiments.

Results from a literature search with PubMed suggests that commonly used pain medications such as opioids [1-3] and non-steroidal anti-inflammatory agents [4-6] may alter the response to bioactive molecules like plant compounds and other drugs. Furthermore, it is well documented that bioactive plant products in Human medicine and Veterinary medicine have the potential for adverse effects [7-9]. Due to the confounding effects of drug-plant compound interactions, pain relieving substances are not routinely administered to laboratory mice in LD₅₀ experiments.

- 1. Hedrich, W.D., et al., *Insights into CYP2B6-mediated drug-drug interactions*. Acta Pharm Sin B. 2016. 6:413-425.
- Mouly, S. et al., Is the clinical relevance of drug-food and drug-herb interactions limited to grapefruit juice and Saint-John's Wort? Pharmacol Res. 2016. S1043-6618(16)30991-4.
- 3. Kohurt, S.J., Interactions_between nicotine and drugs of abuse: A review of preclinical *findings*. Am J Drug Alcohol Abuse. 2016 Sep 2:1-16.
- 4. Russo, N.W., et al., *Aspirin, stroke and_drug-drug interactions*. Vascul Pharmacol. 2016. S1537-1891(16)30269-5.

- 5. Lionetto, L., et al., *Choosing the safest acute therapy during chronic migraine prophylactic treatment: pharmacokinetic and pharmacodynamic considerations.* Expert Opin Drug Metab Toxicol. 2016. 12:399-406.
- 6. Supuran, C.T., *Drug interaction considerations in the therapeutic use of carbonic anhydrase inhibitors.* Expert Opin Drug Metab Toxicol. 2016. 12:423-31.
- 7. Campos, M., et al., *Herb-drug Interactions: An insight into cardiovascular diseases based on case reports.* Cardiovasc Hematol Agents Med Chem. 2016 Oct 7. [Epub ahead of print]
- 8. Singh, D., et al., *Herbs-are they safe enough? an overview*. Crit Rev Food Sci Nutr. 2012. 52:876-98.
- 9. Poppenga, R.H. *Herbal medicine: potential for intoxication and interactions with conventional drugs.* Clin Tech Small Anim Pract. 2002. 17:6-18.